Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
34.67
-1.76 (-4.83%)
Jun 14, 2024, 4:00 PM EDT - Market closed

Celldex Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 1995
Cash & Equivalents
34.8129.4339.1443.8411.23
Upgrade
Short-Term Investments
388.78275.52369.11150.5953.15
Upgrade
Cash & Cash Equivalents
423.6304.95408.25194.4264.38
Upgrade
Cash Growth
38.91%-25.30%109.98%201.98%-31.52%
Upgrade
Receivables
2.630.350.171.81.02
Upgrade
Other Current Assets
5.4712.392.421.621.3
Upgrade
Total Current Assets
431.69317.69410.84197.8466.7
Upgrade
Property, Plant & Equipment
6.647.756.527.267.5
Upgrade
Goodwill and Intangibles
27.1927.1927.1930.6948.69
Upgrade
Other Long-Term Assets
0.110.10.10.040.04
Upgrade
Total Long-Term Assets
33.9335.0433.823856.24
Upgrade
Total Assets
465.63352.74444.65235.84122.93
Upgrade
Accounts Payable
3.493.341.231.051.17
Upgrade
Current Debt
1.611.451.751.331.94
Upgrade
Other Current Liabilities
26.0213.8313.5511.838.53
Upgrade
Total Current Liabilities
31.1318.6116.5314.2111.64
Upgrade
Long-Term Debt
0.932.591.32.151.71
Upgrade
Other Long-Term Liabilities
4.45.337.3510.1215.55
Upgrade
Total Long-Term Liabilities
5.337.928.6512.2817.26
Upgrade
Total Liabilities
36.4626.5325.1826.4828.91
Upgrade
Total Debt
2.544.033.043.483.66
Upgrade
Debt Growth
-36.97%32.58%-12.61%-4.81%-
Upgrade
Retained Earnings
-1,397.36-1,255.93-1,143.61-1,073.1-1,013.32
Upgrade
Comprehensive Income
3.311.261.892.592.62
Upgrade
Shareholders' Equity
429.17326.2419.48209.3694.03
Upgrade
Net Cash / Debt
421.06300.92405.21190.9460.73
Upgrade
Net Cash / Debt Growth
39.92%-25.74%112.22%214.43%-35.41%
Upgrade
Net Cash Per Share
8.696.429.456.444.19
Upgrade
Working Capital
400.57299.08394.31183.6455.06
Upgrade
Book Value Per Share
8.866.969.797.066.48
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).